Epilepsies, Myoclonic: all 92 studies

Page 1 of 1. Open to participants first (21), then studies with results posted, then the rest; newest registration first within each.

• A Fully Remote Feasibility Trial of Phenylbutyrate for SLC6A1-Related DisordersRecruitingNCT07847918Phase 2
• Biomarkers of Neurodegeneration, Synaptic Plasticity and Neuroinflammation in Dravet SyndromeNot yet recruitingNCT07801404
• A Study to Evaluate the Safety and Pharmacokinetics of RC001 in Children With Dravet SyndromeRecruitingNCT07675746Early Phase 1
• ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet SyndromeRecruitingNCT07531745Phase 1/2
• Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene MutationRecruitingNCT07251673
• Clinical Utility of Reduced EEG Home Monitoring in Fenfluramine Titration for Dravet and LGSEnrolling by invitationNCT07225231Not applicable
• The FINTEPLA as an Anti-SUDEP Therapy in Dravet Syndrome ProjectRecruitingNCT07112365Phase 4
• A PET-MRI Study of Serotoninergic Brainstem Pathway in Patients With Dravet SyndromeRecruitingNCT07013331Not applicable
• A Study to Investigate the Transition of Children From 'Artisanal" Cannabidiol (CBD) to EpidiolexNot yet recruitingNCT06924827Phase 4
• A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)Enrolling by invitationNCT06908226Phase 3
• CBD Delivery with the A-Synaptic GT4 Transdermal Delivery System in with Dravet Syndrome And/or Lennox-Gastaut SyndromeNot yet recruitingNCT06738732Phase 1/2
• Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of AgeRecruitingNCT06598449Phase 4
• SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United KingdomRecruitingNCT06504511
• BMB-101 in Absence Epilepsy and DEERecruitingNCT06401538Phase 2
• EXploring novEl Molecular Determinants of DRAvet Syndrome Phenotype HeterogeneityEnrolling by invitationNCT06371794Not applicable
• Intermediate-Size Expanded Access Protocol (EAP) for LP352AvailableNCT06149663
• GABA Biomarkers in Dravet SyndromeRecruitingNCT05651204
• Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research InitiativesRecruitingNCT05635266
• A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet SyndromeRecruitingNCT05419492Phase 1/2
• Multicentre Real-life Follow-up Study of Rare Epileptic Syndromes in Children and AdolescentsRecruitingNCT05126914
• A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet SyndromeRecruitingNCT04462770Phase 3
• A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to FenfluramineTerminatedNCT06422377Phase 3Results posted
• Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic SeizuresTerminatedNCT05288283Phase 3Results posted
• A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut SyndromeTerminatedNCT05163314Phase 3Results posted
• A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet SyndromeCompletedNCT04940624Phase 3Results posted
• A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet SyndromeTerminatedNCT04572243Phase 3Results posted
• Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled SeizuresTerminatedNCT04485104Phase 3Results posted
• A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut SyndromeCompletedNCT03936777Phase 3Results posted
• A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic EncephalopathiesCompletedNCT03650452Phase 2Results posted
• A Study of Soticlestat in Adults and Children With Rare EpilepsiesTerminatedNCT03635073Phase 2Results posted
• A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet SyndromeTerminatedNCT03299842Phase 3Results posted
• A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet SyndromeCompletedNCT02926898Phase 3Results posted
• An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet SyndromeCompletedNCT02823145Phase 3Results posted
• The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe EpilepsyTerminatedNCT02815540Phase 1/2Results posted
• A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet SyndromeCompletedNCT02682927Phase 3Results posted
• A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial DiseaseTerminatedNCT02473445Phase 2Results posted
• Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure DisorderCompletedNCT02318602Phase 3Results posted
• GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet SyndromeCompletedNCT02224703Phase 3Results posted
• An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut SyndromesCompletedNCT02224573Phase 3Results posted
• Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet SyndromeTerminatedNCT02187809Phase 3Results posted
• Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)CompletedNCT02091375Phase 3Results posted
• A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)CompletedNCT02091206Phase 2Results posted
• Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial DiseaseCompletedNCT02023866Phase 2Results posted
• Verapamil as Therapy for Children and Young Adults With Dravet SyndromeCompletedNCT01607073Phase 2Results posted
• Applicability and Effectiveness of Remote Occupational TherapyCompletedNCT07592650
• Bioavailability of Stiripentol After Single Oral Dose of Capsule vs Suspension in Healthy Subjects (STILIQ)CompletedNCT07176832Phase 1
• A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet SyndromeActive, not recruitingNCT06872125Phase 3
• A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)Active, not recruitingNCT06660394Phase 3
• A Study on Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS) in Children, Teenagers and Adults in PortugalWithdrawnNCT06395792
• A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet SyndromeActive, not recruitingNCT06283212Phase 1/2
• A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet SyndromeCompletedNCT06118255Phase 3
• A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)Active, not recruitingNCT06112275Phase 1/2
• A Study to Gather Information About Overall Occurrence and New Cases of Dravet and Lennox-Gastaut Syndromes in Children, Teenagers and Adults in SpainCompletedNCT05982717
• Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic EncephalopathyCompletedNCT05626634Phase 2
• Fenfluramine for Adult Dravet PatientsTerminatedNCT05560282Phase 3
• Retrospective Non-interventional Study of Stiripentol Use in Dravet Patients in the USACompletedNCT05544058
• Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALYActive, not recruitingNCT05485831
• Neurodevelopmental Impact of Epilepsy on Autonomic Function in Dravet SyndromeActive, not recruitingNCT05472389Not applicable
• Observational Study in Patients With Cyclin-dependent Kinase-like 5 Deficiency DisorderActive, not recruitingNCT05373719
• Study to Investigate LP352 in Subjects With Developmental and Epileptic EncephalopathiesCompletedNCT05364021Phase 1/2
• LEONIDaS Caregivers StudyWithdrawnNCT05140122
• Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral SolutionActive, not recruitingNCT05044819Phase 4
• Fenfluramine and CognitionCompletedNCT05026398Phase 4
• An Open-Label Extension Study of STK-001 for Patients With Dravet SyndromeActive, not recruitingNCT04740476Phase 2
• Transcranial Magnetic Stimulation to Measure Cortical Excitability in Dravet SyndromeStatus unknownNCT04614506
• Research on Cognitive Effect of Cannabidiol on Dravet Syndrome and Lennox-Gastaut SyndromeGastaut SyndromeStatus unknownNCT04611438Phase 3
• Natural History Study of Infants and Children With Developmental and Epileptic EncephalopathiesTerminatedNCT04537832
• International CDKL5 RegistrySuspendedNCT04486768
• Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory EpilepsiesNo longer availableNCT04457687
• An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet SyndromeCompletedNCT04442295Phase 1/2
• Treatment of Dravet Syndrome With Fenfluramine (Expanded Access Protocol)Approved for marketingNCT04437004
• Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects.CompletedNCT04069689Phase 1
• The Becoming of Children With Doose SyndromeCompletedNCT04048213
• Natural History and Functional Status Study of Patients With Lafora DiseaseCompletedNCT03876522
• Treatment of Gait Disorders in Children With Dravet SyndromeCompletedNCT03857451
• ZX008 Expanded Access ProtocolApproved for marketingNCT03780127
• Early Check: Expanded Screening in NewbornsActive, not recruitingNCT03655223
• A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking CannabidiolCompletedNCT03467113Phase 1
• Turmeric as Treatment in EpilepsyWithdrawnNCT03254680Not applicable
• Cannabidiol in Children With Refractory Epileptic EncephalopathyStatus unknownNCT03024827Phase 1
• The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe EpilepsyWithdrawnNCT02910297
• Neuronal Excitability of HCN1 Channel Mutations in Dravet SyndromeCompletedNCT02896608
• Cardiac Arrhythmias in Dravet SyndromeCompletedNCT02415686
• Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet SyndromeWithdrawnNCT02318563Phase 3
• Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant EpilepsyCompletedNCT02286986Phase 1
• Expanded Access Use of Stiripentol in Dravet Syndrome or Sodium Channel Mutation Epileptic EncephalopathiesNo longer availableNCT02239276
• Genetic Analysis Between Charlotte's Web Responders Versus Non- Responders in a Dravet PopulationCompletedNCT02229032
• Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet SyndromeWithdrawnNCT02174094Phase 3
• Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet SyndromeApproved for marketingNCT01983722
• Compassionate Use of Stiripentol in Dravet SyndromeNo longer availableNCT01835314
• Stiripentol in Dravet SyndromeNo longer availableNCT01533506
• Effect of Levetiracetam on Brain ExcitabilityCompletedNCT00006191

← Epilepsies, Myoclonic overview